DM
CPRX

Deerfield Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Deerfield Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,943,600
Closed -$97.6M – 85
2026
Q1 		$97.6M Sell
3,943,600
-967,561
-20% -$23.1M 1.15% 23
2025
Q4 		$115M Sell
4,911,161
-63,606
-1% -$1.42M 1.46% 21
2025
Q3 		$98M Buy
4,974,767
+2,095,291
+73% +$43.1M 1.5% 18
2025
Q2 		$62.5M Sell
2,879,476
-542,673
-16% -$12.8M 1.13% 23
2025
Q1 		$83M Buy
3,422,149
+289,138
+9% +$6.51M 1.64% 20
2024
Q4 		$65.4M Sell
3,133,011
-3,096,623
-50% -$66.5M 1.24% 23
2024
Q3 		$124M Sell
6,229,634
-2,897,671
-32% -$53.7M 1.85% 13
2024
Q2 		$141M Sell
9,127,305
-3,512
-0% -$54.7K 2.35% 9
2024
Q1 		$146M Buy
9,130,817
+241,916
+3% +$3.65M 2.53% 7
2023
Q4 		$149M Buy
8,888,901
+696,901
+9% +$9.53M 2.76% 6
2023
Q3 		$95.8M Hold
8,192,000
– – 2.11% 15
2023
Q2 		$110M Sell
8,192,000
-2,163,099
-21% -$31.1M 2.35% 11
2023
Q1 		$172M Buy
10,355,099
+4,470,651
+76% +$73.8M 3.83% 4
2022
Q4 		$109M Buy
5,884,448
+988,448
+20% +$15.2M 2.27% 11
2022
Q3 		$62.8M Buy
+4,896,000
New +$58M 1.25% 26

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deerfield Management's CPRX Position: Q2 2026 in Review

Deerfield Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 3,943,600 shares — an estimated $97.6M sold.

Deerfield Management first reported a position in CPRX in Q3 2022 and held it in 15 quarters. The position peaked at $172M in Q1 2023. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Deerfield Management reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Deerfield Management sold 3,943,600 Catalyst Pharmaceutical shares in Q2 2026, an estimated $97.6M.
  • Deerfield Management first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 15 quarters.
  • Deerfield Management's Catalyst Pharmaceutical position peaked at $172M in Q1 2023.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.